IRIS
MERCURIO, VALENTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.534
EU - Europa 2.959
NA - Nord America 2.457
SA - Sud America 441
AF - Africa 125
OC - Oceania 3
Totale 9.519
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.356
SG - Singapore 1.984
RU - Federazione Russa 1.354
IT - Italia 869
CN - Cina 729
BR - Brasile 351
HK - Hong Kong 309
VN - Vietnam 242
DE - Germania 198
NL - Olanda 98
FI - Finlandia 75
GB - Regno Unito 67
FR - Francia 65
IN - India 55
CA - Canada 54
CI - Costa d'Avorio 37
JP - Giappone 34
KR - Corea 33
MX - Messico 33
ZA - Sudafrica 33
AR - Argentina 32
IE - Irlanda 31
LT - Lituania 24
ES - Italia 23
PL - Polonia 23
BD - Bangladesh 21
PT - Portogallo 21
AT - Austria 19
ID - Indonesia 19
EC - Ecuador 18
SE - Svezia 16
UA - Ucraina 16
IQ - Iraq 15
TR - Turchia 14
BE - Belgio 11
CO - Colombia 11
EG - Egitto 10
VE - Venezuela 10
AE - Emirati Arabi Uniti 9
GE - Georgia 9
PK - Pakistan 9
UZ - Uzbekistan 9
MA - Marocco 8
BG - Bulgaria 7
SK - Slovacchia (Repubblica Slovacca) 7
IL - Israele 6
CZ - Repubblica Ceca 5
PE - Perù 5
PH - Filippine 5
SA - Arabia Saudita 5
TN - Tunisia 5
CH - Svizzera 4
CL - Cile 4
HR - Croazia 4
RO - Romania 4
UY - Uruguay 4
BJ - Benin 3
BO - Bolivia 3
ET - Etiopia 3
JM - Giamaica 3
KE - Kenya 3
LV - Lettonia 3
RS - Serbia 3
AM - Armenia 2
AO - Angola 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BS - Bahamas 2
CM - Camerun 2
DZ - Algeria 2
GH - Ghana 2
GR - Grecia 2
IR - Iran 2
JO - Giordania 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LY - Libia 2
MK - Macedonia 2
MU - Mauritius 2
NO - Norvegia 2
NP - Nepal 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
TZ - Tanzania 2
YE - Yemen 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AU - Australia 1
BH - Bahrain 1
CV - Capo Verde 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GM - Gambi 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
HT - Haiti 1
KH - Cambogia 1
LB - Libano 1
Totale 9.500
Salva come PNG Salva come JPEG
Città #
Singapore 951
Moscow 351
Hong Kong 308
Chandler 305
Ashburn 257
Beijing 213
Hefei 189
Santa Clara 122
Naples 116
San Jose 106
Ho Chi Minh City 81
Los Angeles 75
Millbury 71
Lawrence 67
Munich 67
Dallas 55
Des Moines 51
Amsterdam 50
Boston 50
Redondo Beach 46
Buffalo 42
Milan 40
Napoli 40
New York 40
Dong Ket 38
Rome 36
Hanoi 34
Seoul 33
São Paulo 33
Nanjing 30
Helsinki 29
Frankfurt am Main 27
Turku 26
Wilmington 23
Palermo 22
Seattle 21
Denver 18
Falkenstein 18
The Dalles 18
Tokyo 18
Houston 17
Montreal 17
Orem 17
Brooklyn 16
Nuremberg 16
Sennori 16
Bologna 15
Johannesburg 15
London 15
Atlanta 14
Caserta 14
Chicago 14
Fairfield 14
Mexico City 14
Shenyang 14
Council Bluffs 13
Haiphong 13
Princeton 13
Toronto 13
Bari 12
Chennai 12
Poplar 12
Warsaw 12
Belo Horizonte 11
Catania 11
Lappeenranta 11
Shanghai 11
Kochi 10
Montijo 10
Ottawa 10
Pune 10
Rio de Janeiro 10
Turin 10
Woodbridge 10
Bogotá 9
Changsha 9
Dublin 9
Düsseldorf 9
Stockholm 9
Biên Hòa 8
Chengdu 8
Manchester 8
Manfredonia 8
Marcianise 8
Roubaix 8
Salt Lake City 8
Vienna 8
Guayaquil 7
Hebei 7
Tashkent 7
Tbilisi 7
Ankara 6
Battipaglia 6
Brescia 6
Cagliari 6
Foggia 6
Menlo Park 6
Nanchang 6
Padova 6
Pisa 6
Totale 4.750
Salva come PNG Salva come JPEG
Nome #
Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA/ICOS risk tool in real-world practice 695
The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity 163
Right ventricular failure in left heart disease: from pathophysiology to clinical manifestations and prognosis 149
Meccanismi molecolari della cardiotossicità indotta da antracicline e radioterapia 142
Antineoplastic drug-induced cardiotoxicity: A redox perspective 140
Cardiac sympathetic dysfunction in pulmonary arterial hypertension: Lesson from left-sided heart failure 134
Inflammatory, Serological and Vascular Determinants of Cardiovascular Disease in Systemic Lupus Erythematosus Patients 129
Adapted recreational football Small Sided Games improves cardiac capacity, body composition and muscular fitness in patients with type 2 diabetes: results from a pilot study 128
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 124
Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue 123
Evaluation of exercise capacity by means of cardiopulmonary exercise testing (CPET) in older adult cancer patients undergoing antineoplastic treatments 119
New drugs, therapeutic strategies, and future direction for the treatment of Pulmonary Arterial Hypertension 119
Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients 119
The use of chest ultrasonography in suspected cases of COVID-19 in the emergency department 119
A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome: A randomized, double-blind, placebo-controlled trial 117
Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan 117
Severe Aortic Valve Regurgitation in Relapsing Polychondritis 116
What is the cardiac impact of chemotherapy and subsequent radiotherapy in lymphoma patients 115
Oxidative stress in anticancer therapies-related cardiac dysfunction 114
Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study 113
Prevention of cardiovascular complications in elderly cancer patients 113
Editorial: Myocardium regeneration and cardioprotection 107
Cancer Risk in the Heart Failure Population: Epidemiology, Mechanisms, and Clinical Implications 107
Novel metrics for risk stratification with nuclear cardiology 106
Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment 105
Redox imbalances in ageing and metabolic alterations: Implications in cancer and cardiac diseases. An overview from the working group of cardiotoxicity and cardioprotection of the Italian society of cardiology (SIC) 105
Mildly Elevated Pulmonary Hypertension: Gray Zone or Already a Disease? 104
Novel Therapeutic Approaches and Targets for the Treatment of Cardiovascular and Immunological Diseases 104
Long-term follow-up in high risk hypertensive patients with carotid dolicoarteriopathies 104
Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. 103
Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs 103
New-Onset Cancer in the HF Population: Epidemiology, Pathophysiology, and Clinical Management 103
The broad spectrum of cardiotoxicities from immunotherapies 99
Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis 99
How can we manage the cardiac toxicity of immune checkpoint inhibitors? 99
Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: A multicenter, double blind, randomized, placebo controlled trial 98
Endocrine alterations are the main determinants of cardiac remodelling in restrictive anorexia nervosa 98
Cardiovascular events and treatment of children with high risk medulloblastoma 98
A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function 97
Time-weighted lactate as a predictor of adverse outcome in acute heart failure 96
Commentary on “Functional Improvement After Outpatient Cardiac Rehabilitation in Acute Coronary Syndrome Patients is not Related to Improvement in Left Ventricular Ejection Fraction” 95
Efficacy and safety of valsartan plus hydroclorothiazide for high blood pressure 94
Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure 94
Innovations in medical therapy of heart failure with reduced ejection fraction 93
Preventing antiblastic drug-related cardiomyopathy: Old and new therapeutic strategies 93
Circulating miR-10b-5p, miR-193a-3p, and miR-1-3p Are Deregulated in Patients with Heart Failure and Correlate with Hormonal Deficiencies 92
Metabolomic perspectives in antiblastic cardiotoxicity and cardioprotection 90
Molecular Mechanisms of Cardiovascular Damage Induced by Anti-HER-2 Therapies 89
Peripheral Vascular Function in Dilated Cardiomyopathy of Different Etiology 89
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors 88
Blood lactate in mild and moderate ARDS secondary to SARS COV 2 84
Effects of a nutraceutical combination on left ventricular remodeling and vasoreactivity in subjects with the metabolic syndrome 84
Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF 84
The right heart in patients with cancer. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology 84
Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors 82
Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond 80
Pharmacovigilating cardiotoxicity of immune checkpoint inhibitors 80
Prevention of cancer-therapy-related heart failure 80
Causes and outcomes of {ICU} hospitalisations in patients with pulmonary arterial hypertension 79
Pulmonary Hypertension Induced by Anticancer Drugs 79
Sex-related differences in COVID-19 lethality 78
Cardiovascular safety of the tyrosine kinase inhibitor nintedanib 77
Mechanisms of Cardiovascular Damage Induced by Traditional Chemotherapy 76
The effects of Dapagliflozin in a real-world population of HFrEF patients with different hemodynamic profiles: worse is better 76
Right heart dysfunction: from pathophysiologic insights to therapeutic options: a translational overview 75
Cardio-Oncology Challenges in Elderly Patients 74
Pulmonary arterial hypertension and atrial arrhythmias: incidence, risk factors and clinical impact 74
Insulin resistance: Is it time for primary prevention? 74
Beta-blockers in pulmonary arterial hypertension: Time for a second thought? 73
Prognostic impact of diabetes in chronic and acute heart failure 73
Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC) 72
Risk Stratification of Patients with Pulmonary Arterial Hypertension: The Role of Echocardiography 71
Management of cancer patients at high and very-high risk of cardiotoxicity: Main questions and answers 71
Inflammatory Mechanisms in the Pathogenesis of Pulmonary Arterial Hypertension: Recent Advances 71
A nutraceutical combination reduces left ventricular mass in subjects with metabolic syndrome e and left ventricular hypertrophy: A multicenter, randomized, double-blind, placebo-controlled trial 70
Sacubitril/valsartan in patients listed for heart transplantation: effect on physical frailty 70
Effect of Sacubitril-Valsartan in reducing depression in patients with advanced heart failure 68
Right ventricular dysfunction in chronic heart failure: clinical laboratory and echocardiographic characteristics. (the RIVED-CHF registry) 66
Right ventricular function as assessed by cardiac magnetic resonance imaging-derived strain parameters compared to high-fidelity micromanometer catheter measurements 65
Relevance of comorbidities on initial combination therapy in pulmonary arterial hypertension 60
A comprehensive echocardiographic method for risk stratification in pulmonary arterial hypertension 56
Inflammation at the crossroad between cancer and heart failure 55
Effects of sacubitril/valsartan on renal function and outcome in patients with heart failure and reduced ejection fraction: an Italian cohort study 55
Non-cardiovascular comorbidities in heart failure patients and their impact on prognosis 52
Patient phenotype profiling using echocardiography and natriuretic peptides to personalise heart failure therapy 48
Effect of sacubitril/valsartan on cardiac remodeling compared with other renin-angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples 48
Cardiovascular and metabolic effects of Berberine 48
Non-invasive CPAP in mild and moderate ARDS secondary to SARS-CoV-2 47
Pulmonary arterial hypertension: sex-specific differences and outcomes 46
Poor survival in patients with scleroderma and pulmonary hypertension due to heart failure with preserved ejection fraction 46
Lung ultrasound as diagnostic tool for SARS-CoV-2 infection 46
Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan‒tadalafil in pulmonary arterial hypertension 44
Improvement in Right Ventricular Strain with Ambrisentan and Tadalafil Upfront Therapy in Scleroderma-associated Pulmonary Arterial Hypertension 43
Echocardiographic assessment and clinical implication of functional tricuspid regurgitation in heart failure with reduced or preserved ejection fraction (ECLIPSE-HF) : Rationale and design of the study 42
Right ventricular longitudinal strain is diminished in systemic sclerosis compared with idiopathic pulmonary arterial hypertension 42
The multifaceted mechanisms of nitroxyl in heart failure: inodilator or ‘only’ vasodilator? 42
Risk assessment in scleroderma patients with newly diagnosed pulmonary arterial hypertension: Application of the ESC/ERS risk prediction model 41
Response to pulmonary vasodilator treatment in a former smoker with combined interstitial lung disease complicated by pulmonary hypertension: Case report and review of the literature 41
Assessment of right ventricular reserve utilizing exercise provocation in systemic sclerosis 41
Stress Echocardiographic Prediction of Emerging Pulmonary Vascular Disease in Systemic Sclerosis 39
Totale 9.232
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.672
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.672
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021129 0 0 0 0 0 0 28 8 13 24 12 44
2021/2022432 4 0 6 14 8 12 24 31 27 29 103 174
2022/20231.018 85 67 58 79 114 88 46 130 190 86 49 26
2023/2024663 44 70 73 52 34 81 33 83 20 27 103 43
2024/20253.160 145 186 22 43 61 220 308 235 163 337 1.109 331
2025/20263.931 680 457 690 514 1.156 283 151 0 0 0 0 0
Totale 9.764